Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 6465793, 9 pages
http://dx.doi.org/10.1155/2016/6465793
Review Article

Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson’s Disease

1Golgi Cenci Foundation, Abbiategrasso, 20081 Milan, Italy
2Geriatric Unit and Gerontology-Geriatrics Research Laboratory, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013 Foggia, Italy

Received 23 October 2015; Revised 5 January 2016; Accepted 10 January 2016

Academic Editor: Jan O. Aasly

Copyright © 2016 Letizia Polito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the alpha-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, “α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6469–6473, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Lesage and A. Brice, “Parkinson's disease: from monogenic forms to genetic susceptibility factors,” Human Molecular Genetics, vol. 18, no. 1, pp. R48–R59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Verstraeten, J. Theuns, and C. Van Broeckhoven, “Progress in unraveling the genetic etiology of Parkinson disease in a genomic era,” Trends in Genetics, vol. 31, no. 3, pp. 140–149, 2015. View at Publisher · View at Google Scholar
  5. V. Dias, E. Junn, and M. M. Mouradian, “The role of oxidative stress in parkinson's disease,” Journal of Parkinson's Disease, vol. 3, no. 4, pp. 461–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Nalls, N. Pankratz, C. M. Lill et al., “Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease,” Nature Genetics, vol. 46, no. 9, pp. 989–993, 2014. View at Publisher · View at Google Scholar
  7. P. A. Ballard, J. W. Tetrud, and J. W. Langston, “Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases,” Neurology, vol. 35, no. 7, pp. 949–956, 1985. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Priyadarshi, S. A. Khuder, E. A. Schaub, and S. Shrivastava, “A meta-analysis of Parkinson's disease and exposure to pesticides,” Neurotoxicology, vol. 21, no. 4, pp. 435–440, 2000. View at Google Scholar · View at Scopus
  9. M. Van der Mark, M. Brouwer, H. Kromhout, P. Nijssen, A. Huss, and R. Vermeulen, “Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results,” Environmental Health Perspectives, vol. 120, no. 3, pp. 340–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Steenland, M. J. Hein, R. T. Cassinelli II et al., “Polychlorinated biphenyls and neurodegenerative disease mortality in an occupational cohort,” Epidemiology, vol. 17, no. 1, pp. 8–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Goldman, P. J. Quinlan, G. W. Ross et al., “Solvent exposures and Parkinson disease risk in twins,” Annals of Neurology, vol. 71, no. 6, pp. 776–784, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Gorell, C. C. Johnson, B. A. Rybicki et al., “Occupational exposures to metals as risk factors for Parkinson's disease,” Neurology, vol. 48, no. 3, pp. 650–658, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. M. M. Finkelstein and M. Jerrett, “A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities,” Environmental Research, vol. 104, no. 3, pp. 420–432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Proukakis, C. G. Dudzik, T. Brier et al., “A novel α-synuclein missense mutation in Parkinson disease,” Neurology, vol. 80, no. 11, pp. 1062–1064, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Lesage, M. Anheim, F. Letournel et al., “G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome,” Annals of Neurology, vol. 73, no. 4, pp. 459–471, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. A. B. Singleton, M. Farrer, J. Johnson et al., “α-synuclein locus triplication causes Parkinson’s disease,” Science, vol. 302, no. 5646, article 841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Poulopoulos, O. A. Levy, and R. N. Alcalay, “The neuropathology of genetic Parkinson's disease,” Movement Disorders, vol. 27, no. 7, pp. 831–842, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. B. Singleton, M. J. Farrer, and V. Bonifati, “The genetics of Parkinson's disease: progress and therapeutic implications,” Movement Disorders, vol. 28, no. 1, pp. 14–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. R. Cookson, “The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease,” Nature Reviews Neuroscience, vol. 11, no. 12, pp. 791–797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Zimprich, S. Biskup, P. Leitner et al., “Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology,” Neuron, vol. 44, no. 4, pp. 601–607, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. D. G. Healy, M. Falchi, S. S. O'Sullivan et al., “Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study,” The Lancet Neurology, vol. 7, no. 7, pp. 583–590, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. L. J. Ozelius, G. Senthil, R. Saunders-Pullman et al., “LRRK2 G2019S as a cause of Parkinson's disease in ashkenazi jews,” The New England Journal of Medicine, vol. 354, no. 4, pp. 424–425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Lesage, A. Dürr, M. Tazir et al., “LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs,” The New England Journal of Medicine, vol. 354, no. 4, pp. 422–423, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Vilariño-Güell, C. Wider, O. A. Ross et al., “VPS35 mutations in parkinson disease,” American Journal of Human Genetics, vol. 89, no. 1, pp. 162–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Vilariño-Güell, A. Rajput, A. J. Milnerwood et al., “DNAJC13 mutations in Parkinson disease,” Human Molecular Genetics, vol. 23, no. 7, pp. 1794–1801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M.-C. Chartier-Harlin, J. C. Dachsel, C. Vilariño-Güell et al., “Translation initiator EIF4G1 mutations in familial parkinson disease,” American Journal of Human Genetics, vol. 89, no. 3, pp. 398–406, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Bonifati, P. Rizzu, M. J. van Baren et al., “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism,” Science, vol. 299, no. 5604, pp. 256–259, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Kitada, S. Asakawa, N. Hattori et al., “Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism,” Nature, vol. 392, no. 6676, pp. 605–608, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al., “Hereditary early-onset Parkinson's disease caused by mutations in PINK1,” Science, vol. 304, no. 5674, pp. 1158–1160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Paisan-Ruiz, K. P. Bhatia, A. Li et al., “Characterization of PLA2G6 as a locus for dystonia-parkinsonism,” Annals of Neurology, vol. 65, no. 1, pp. 19–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Shojaee, F. Sina, S. S. Banihosseini et al., “Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays,” The American Journal of Human Genetics, vol. 82, no. 6, pp. 1375–1384, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Ramirez, A. Heimbach, J. Gründemann et al., “Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase,” Nature Genetics, vol. 38, no. 10, pp. 1184–1191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Elbaz, F. Grigoletto, M. Baldereschi et al., “Familial aggregation of Parkinson's disease: a population-based case-control study in Europe,” Neurology, vol. 52, no. 9, pp. 1876–1882, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. T. T. Warner and A. H. V. Schapira, “Genetic and environmental factors in the cause of Parkinson's disease,” Annals of Neurology, vol. 53, supplement 3, pp. S16–S25, 2003. View at Publisher · View at Google Scholar
  37. V. Bonifati, “LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)—linking familial and sporadic Parkinson's disease,” Neurochemical Research, vol. 32, no. 10, pp. 1700–1708, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. D. M. Maraganore, M. de Andrade, A. Elbaz et al., “Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease,” The Journal of the American Medical Association, vol. 296, no. 6, pp. 661–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. E. R. Martin, W. K. Scott, M. A. Nance et al., “Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease,” The Journal of the American Medical Association, vol. 286, no. 18, pp. 2245–2250, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Swan and R. Saunders-Pullman, “The association between β-glucocerebrosidase mutations and parkinsonism,” Current Neurology and Neuroscience Reports, vol. 13, article 368, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Gan-Or, L. J. Ozelius, A. Bar-Shira et al., “The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease,” Neurology, vol. 80, no. 17, pp. 1606–1610, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. N. E. Mencacci, I. U. Isaias, M. M. Reich et al., “Parkinson's disease in GTP cyclohydrolase 1 mutation carriers,” Brain, vol. 137, no. 9, pp. 2480–2492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Simón-Sánchez, C. Schulte, J. M. Bras et al., “Genome-wide association study reveals genetic risk underlying Parkinson's disease,” Nature Genetics, vol. 41, no. 12, pp. 1308–1312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Satake, Y. Nakabayashi, I. Mizuta et al., “Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease,” Nature Genetics, vol. 41, no. 12, pp. 1303–1307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. C. M. Tanner, F. Kame, G. W. Ross et al., “Rotenone, paraquat, and Parkinson's disease,” Environmental Health Perspectives, vol. 119, no. 6, pp. 866–872, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Wirdefeldt, H.-O. Adami, P. Cole, D. Trichopoulos, and J. Mandel, “Epidemiology and etiology of Parkinson's disease: a review of the evidence,” European Journal of Epidemiology, vol. 26, supplement 1, pp. S1–S58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. M. A. Hernán, B. Takkouche, F. Caamaño-Isorna, and J. J. Gestal-Otero, “A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease,” Annals of Neurology, vol. 52, no. 3, pp. 276–284, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Zschiedrich, I. R. König, N. Brüggemann et al., “MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?” Journal of Neurology, vol. 256, no. 1, pp. 115–120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Dutheil, P. Beaune, C. Tzourio, M.-A. Loriot, and A. Elbaz, “Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease,” Archives of Neurology, vol. 67, no. 6, pp. 739–745, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Narayan, J. S. Sinsheimer, K. C. Paul et al., “Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease,” Environmental Research, vol. 143, pp. 98–106, 2015. View at Publisher · View at Google Scholar
  51. A. D. Manthripragada, S. Costello, M. G. Cockburn, J. M. Bronstein, and B. Ritz, “Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease,” Epidemiology, vol. 21, no. 1, pp. 87–94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Narayan, Z. Liew, K. Paul et al., “Household organophosphorus pesticide use and Parkinson's disease,” International Journal of Epidemiology, vol. 42, no. 5, Article ID dyt170, pp. 1476–1485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Elbaz, C. Levecque, J. Clavel et al., “CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease,” Annals of Neurology, vol. 55, no. 3, pp. 430–434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Deng, B. Newman, M. P. Dunne, P. A. Silburn, and G. D. Mellick, “Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease,” Annals of Neurology, vol. 55, no. 6, p. 897, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. F. D. Dick, G. De Palma, A. Ahmadi et al., “Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study,” Occupational and Environmental Medicine, vol. 64, no. 10, pp. 673–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. R. A. Popat, S. K. Van Den Eeden, C. M. Tanner et al., “Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease,” European Journal of Neurology, vol. 18, no. 5, pp. 756–765, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J. B. Wilk, J. E. Tobin, O. Suchowersky et al., “Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD study,” Neurology, vol. 67, no. 12, pp. 2206–2210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Deng, B. Newman, M. P. Dunne, P. A. Silburn, and G. D. Mellick, “Case-only study of interactions between genetic polymorphisms of GSTM1, P1, T1 and Z1 and smoking in Parkinson's disease,” Neuroscience Letters, vol. 366, no. 3, pp. 326–331, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. S. N. P. Kelada, H. Checkoway, S. L. R. Kardia et al., “5′ and 3′ region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study,” Human Molecular Genetics, vol. 15, no. 20, pp. 3055–3062, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. B. R. Ritz, A. D. Manthripragada, S. Costello et al., “Dopamine transporter genetic variants and pesticides in Parkinson's disease,” Environmental Health Perspectives, vol. 117, no. 6, pp. 964–969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Checkoway, G. M. Franklin, P. Costa-Mallen et al., “A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease,” Neurology, vol. 50, no. 5, pp. 1458–1461, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. C.-S. Fong, R.-M. Wu, J.-C. Shieh et al., “Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease,” Clinica Chimica Acta, vol. 378, no. 1-2, pp. 136–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. D. B. Hancock, E. R. Martin, J. M. Vance, and W. K. Scott, “Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease,” Neurogenetics, vol. 9, no. 4, pp. 249–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. T. H. Hamza, H. Chen, E. M. Hill-Burns et al., “Genome-wide gene-environment study identifies glutamate receptor gene grin2a as a parkinson's disease modifier gene via interaction with coffee,” PLoS Genetics, vol. 7, no. 8, Article ID e1002237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Yamada-Fowler, M. Fredrikson, and P. Söderkvist, “Caffeine interaction with glutamate receptor gene GRIN2A: Parkinson's disease in Swedish population,” PLoS ONE, vol. 9, no. 6, Article ID e99294, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. D. S. Miller, “Regulation of ABC transporters at the blood-brain barrier,” Clinical Pharmacology & Therapeutics, vol. 97, no. 4, pp. 395–403, 2015. View at Publisher · View at Google Scholar
  67. M. Droździk, M. Białecka, K. Myśliwiec, K. Honczarenko, J. Stankiewicz, and Z. Sych, “Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease,” Pharmacogenetics, vol. 13, no. 5, pp. 259–263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Kiyohara, Y. Miyake, M. Koyanagi et al., “MDR1 C3435T polymorphism and interaction with environmental factors in risk of Parkinson's disease: a case-control study in Japan,” Drug Metabolism and Pharmacokinetics, vol. 28, no. 2, pp. 138–143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. P.-C. Lee, S. L. Rhodes, J. S. Sinsheimer, J. Bronstein, and B. Ritz, “Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure,” Environment International, vol. 56, pp. 42–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. C.-S. Fong, C.-W. Cheng, and R.-M. Wu, “Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease,” Acta Neurologica Taiwanica, vol. 14, no. 2, pp. 55–60, 2005. View at Google Scholar · View at Scopus
  71. M. C. Taylor, D. G. Le Couteur, G. D. Mellick, and P. G. Board, “Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a caucasian population,” Journal of Neural Transmission, vol. 107, no. 8-9, pp. 979–983, 2000. View at Publisher · View at Google Scholar · View at Scopus
  72. U. M. Zanger, S. Raimundo, and M. Eichelbaum, “Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 369, no. 1, pp. 23–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. N. K. Singh, B. D. Banerjee, K. Bala, M. Chhillar, and N. Chhillar, “Gene-gene and gene-environment interaction on the risk of Parkinson's disease,” Current Aging Science, vol. 7, no. 2, pp. 101–109, 2014. View at Google Scholar
  74. S. M. Goldman, F. Kamel, G. W. Ross et al., “Genetic modification of the association of paraquat and Parkinson's disease,” Movement Disorders, vol. 27, no. 13, pp. 1652–1658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. P. M. Rappold, M. Cui, A. S. Chesser et al., “Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 51, pp. 20766–20771, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. S. N. Kelada, P. Costa-Mallen, L. G. Costa et al., “Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease,” NeuroToxicology, vol. 23, no. 4-5, pp. 515–519, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Miyake, K. Tanaka, W. Fukushima et al., “SNCA polymorphisms, smoking, and sporadic Parkinson's disease in Japanese,” Parkinsonism and Related Disorders, vol. 18, no. 5, pp. 557–561, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. J. A. Mortimer, A. R. Borenstein, and L. M. Nelson, “Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis,” Neurology, vol. 79, no. 11, pp. 1174–1180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Rentschler, L. Covolo, A. A. Haddad, R. G. Lucchini, S. Zoni, and K. Broberg, “ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese,” NeuroToxicology, vol. 33, no. 4, pp. 697–702, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. K. C. Paul, J. S. Sinsheimer, S. L. Rhodes, M. Cockburn, J. Bronstein, and B. Ritz, “Organophosphate pesticide exposures, nitric oxide synthase gene variants, and gene-pesticide interactions in a case-control study of Parkinson's disease, California (USA),” Environmental Health Perspectives, 2015. View at Publisher · View at Google Scholar
  81. I. Ahmed, P.-C. Lee, C. M. Lill et al., “Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease,” PLoS Genetics, vol. 10, no. 11, Article ID e1004788, 2014. View at Publisher · View at Google Scholar · View at Scopus